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Unnatural (+)-physostigmine (2) inhibited acetylcholinesterase (AChE) from electric eel considerably less 
than natural (-)-physostigmine (l), but 2 may because of its possible lower toxicity still be an interesting 
anticholinesterase agent. (-)-Eseroline (3), a major metabolite of (-)-physostigmine (1) and a potent nar- 
cotic analgetic, and its unnatural (+)-antipode (4), were both poor inhibitors of the enzyme. (-)-Dihydrose- 
cophysostigmine (5) a ring-open analog of (-)-physostigmine was less, but (-)-N-methylphysostigmine (6) 
much more potent than the natural alkaloid. The availability of compounds related to (-)- and (+)-physo- 
stigmine by improved chemical synthesis suggests that further structural variation may well lead to other 
biologically interesting AChE inhibitors. 
Physostigmine (Eserine) 
1, INTRODUCTION 
Regulation of acetylcholine turnover and level in 
neurons and synaptic junctions may play an im- 
portant role in a number of neurologic disorders, 
particularly Alzheimer’s disease, myasthenia 
gravis, and anticholinesterase poisoning. The 
alkaloid ( - )-physostigmine (l), also called ( - )- 
eserine, is known for its antiacetylcholinesterase 
properties, and the way it interferes with the en- 
zyme is rather well understood [l]. Our aim to 
reinvestigate compounds related to this alkaloid, 
and to perform a qualitative structure-activity 
study, was prompted by a much improved syn- 
thesis of (+)-Nl-noreseroline O-methyl ether, and 
its optical resolution using urea derivatives [2,3], 
giving easy access to a wide variety of natural and 
unnatural analogs of physostigmine. We wanted to 
confirm that unnatural ( + )-physostigmine (2), 
found to be a much less potent inhibitor of 
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Eseroline Cholinesterase 
erythrocyte acetylcholinesterase (AChE) [4], was 
also less potent in our assay. We furthermore in- 
cluded the ring-open analog 5 of (-)- 
physostigmine, ( - )-N-methylphysostigmine (6), as 
well as the two phenols (-)- and (+)-eseroline (3 
and 4, respectively) hoping that the already 
established qualitative profile of structure and 
anti-cholinesterase activity of compounds related 
to physostigmine [4] could be ascertained. 
2. MATERIALS AND METHODS 
( - )-Physostigmine salicylate (1) was purchased 
from Fluka (Hauppauge, NY). The salicylate of 
( + )-physostigmine (2) was obtained by reaction of 
( + )-eseroline (4) prepared by total synthesis [2-41, 
with methyl isocyanate, and treatment of the free 
base with salicylic acid in ether. ( -)-Eseroline (3) 
was prepared from 1 as in [5], and converted into 
its sulfate salt with sulfuric acid in acetone. ( -)- 
Dihydrosecophysostigmine (5), obtained earlier 
from 1 by reduction with zinc in HCl [6], was 
prepared here by reduction with sodium 
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No. Name Molecular Camp. Formula M,W. M.p. Remarks 
f - LPhysostigmine- 
coon 
0 salicylate * C22H27N305 413.47 182-1840 -70.59 
Inatural) 
Oz;m . 6"" 
CM3 
A” &H 3 3 ic50.8 in CHCI,) 
I+)-Physostigmine- 
COUH 
0 
salicylate * C2ZH27N305 "~fQ--J--J . &" 413.47 f80-182° +67.3(’ 
(unnatural) I I (c-O.6 in CHCI,) 
0 
(-- )-Eseroline- 
sulfate ‘S C~HzoN205S ““Q$.J l HIS04 316.38 210-212~ -11s.4* hygros. 
I I (~1.1 in MeOH) 
@ 
ffl-Esaroline- 
sulfate A Ct3H20N205S 
""Q-$-J ‘ Hg4 316.38 200.20@ + 116.0“ hygros. 
I1 bl.1 in MeOH) 
0 
~-)-~ihydro-phy~- 
stigmine-sulfate 0 C~H2sN30sS “~:Q$-N:, 
. H,SOjO, 375.44 165.170° +13.1° extremely 
I (c=1.2 in MeOH) hygros. 
@ 
(-~-N-Me~yl- 
p)lysostigmine ’ C16H23N302 Ox:Q&zJ 289.38 oil -64.20 
I I ic= 1.4 in CHCI~I 
cyanoborohydride in aqueous methanol, in the 
presence of a catalytic amount of HCI, and con- 
verted to its sulfate salt in acetone. (-j-N- 
Methylphysosti~mine (6) was prepared from 3 by 
reaction with dimethylcarbamoyl chloride in 
pyridine. Physical data obtained for the com- 
pounds described are listed in table I. 
Affinity-purified electric eel AChE was prepared 
in-house according to Y~amura et al. [7] for 
guinea pig brain. Acetylthiocholine and 
5,5 ‘-dithiobis(2-~trobenzoic acid) (DTNB) were 
purchased from Sigma (St. Louis, MO). Buffers 
and other chemicals used were analytical reagent 
grade. 
AChE activity was determined calorimetrically 
using acetylthiocholine as the substrate by a 
modified micro Ellman AChE assay [g], as 
described by Brogdon and Dickinson [9]. All reac- 
tions were carried out in 100 mM potassium 
phosphate buffer (pH 7.4) at room temperature. In 
a typical assay 40 ~1 buffer, 30 ~1 enzyme prepara- 
tion, and 30 /II test compound solution were mixed 
and kept for 15 min. Enzymatic reaction was in- 
itiated by adding to this mixture 20081 solution 
containing acetylthiochohne and DTNB. The time 
course of acetylthiocholine hydrolysis by AChE 
was determined by monitoring the increase of 
yehow color produced from the reaction of 
thiocholine with dithiobisnitrobenzoate ion at a 
wavelength of 414 nm, 
3. RESULTS AND DISCUSSION 
We confirm that inhibition of AChE from elec- 
tric eel by natural ( -)-physostigmine (l), as shown 
in table 2, is enantioselective, and that unnatural 
(~ )-physostigmine (2) is about 12%times less po- 
tent in this assay. (-)-Eseroline (3), a major 
metabolite of ( - ~-physostigmine and a potent nar- 
Table 2 
Relative anticholinesterase potencies of physostigmine 
derivatives 
Compound ICso W) 
(-)-N-Methylphysostigmine 1.8 x lo-” 
(- )-Physostigmine salicylate 4.0 x 1o-9 
( - )-~ihydrosecophysosti~ine sulfate 1 .O X lo-’ 
( + )-Physostigmine salicylate 5,o x lo-? 
( - )-Eseroline sulfate 1.5 x 1o-6 
( f )-Eseroline sulfate 7.0 x 1o-6 
ICsa (test compound concentration required to inhibit 
50% eel AChE in vitro) values were obtained from plots 
of enzyme activity vs concentration of compounds 
shown in fig.1 
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cotic analgetic ]lO,ll], and its optical isomer (i-)- 
eseroline (4) [I l] were, as shown in table 2, several 
hundred times less potent than the natural alkaloid 
1. The ring-open dihydroseco analog 5 is about 
25-times less potent than ( - )-physostigmine from 
which it is derived, suggesting that optimal potency 
may possibly require a tricyclic, rather than a 
bicyclic template [12]. Whether the remarkably 
high potency of ( - )-N-methylphysostigmine (6), 
in agreement with findings made in the 
pyridostigmine family of compounds [ 131, is due 
to steric effects, better lipophili~ity, or other fac- 
tors, remains to be determined, but clearly suggests 
Fig.1. Effects of different est compounds on eel AChE 
activity. AChE was assayed calorimetrically as described 
in section 2. Amount of enzyme activity at each concen- 
tration of the test compounds shown was expressed as 
percent of control activity without any compound 
included in the assay. 0, (- )-physostigmine salicylate; 
0, (+ )-physostigmine salicylate; A , ( - )-eseroline 
sulfate; A , ( + )-eseroline sulfate; r] , ( - )-dihydroseco- 
physostigmine sulfate; m, (-)-~-methylphysostigmine. 
Each point is the mean of 4-8 assays. The assay results 
were highly reproducible with a variation of approx. 5% 
or less from the mean 
that more potent compounds can probably be 
discovered in the physostigmine family. 
Whether (+)-physostigmine (2), because of its 
possibly lower toxicity but still respectable an- 
ticholinesterase activity, is of use in neurologic 
disorders or anti~holinesterase poisoning is being 
investigated. 
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